- Boehringer Ingelheim again joins efforts to fight rabies under this year’s theme for World Rabies Day by GARC: “Rabies: Facts, not Fear”
- Boehringer Ingelheim strives to raise awareness of the disease and its preventio.
Today on World Rabies Day, we commemorate the death of Pasteur who developed the primary rabies vaccine, laying the foundations for rabies prevention. The COVID-19 pandemic has resulted in an upsurge of anti-vax and anti-science movements, yet vaccination and awareness can save lives. this is often why the worldwide Alliance for Rabies Control (GARC) has chosen the theme “Rabies: Facts, not Fear” for World Rabies Day 20211, a notion Boehringer Ingelheim fully supports through longstanding action. the corporate , a worldwide leader in animal health, furthers education and therefore the transmission of crucial knowledge about rabies while developing and supplying lifesaving vaccines.
“Rabies is a particularly dangerous disease, but one we will eliminate through cooperation, especially on awareness and education which are even as important as vaccines,” shares Jean Scheftsik de Szolnok, Member of the Board of Managing Directors with responsibility for Animal Health. “The lives of individuals and animals are interconnected in deep and sophisticated ways. A disease like rabies, from which we will best protect humans by immunizing animals, is exemplary to spotlight that. so as to deliver an efficient vaccination campaign, we’d like a collaborative and transdisciplinary approach among veterinarians, physicians but also environmentalists also as governments, the private sector, associations and institutions.”
Three key facts about rabies anyone should know
As World Rabies Day, observed annually on September 28, may be a pivotal day to draw attention to rabies control, let’s highlight three important facts about the disease subject to popular myths.
Rabies concerns all folks , including those that live outside of Asia and Africa
It is true that these days , 95 percent of human rabies cases occur in Asia and Africa3. However, the disease can still pose a threat to people and animals living within the Americas, Europe, and Oceania. the rationale is that wild animals are reservoirs of the disease even while ongoing vaccination campaigns provide thorough protection for humans and pets. If vaccination efforts lull , there’s a risk of the disease being reintroduced. Human rabies cases are often eliminated, but the disease can’t be eradicated4.
Stray dogs aren’t the sole animals that pose a risk of infection to humans
Although dogs contribute up to 99 percent of all rabies transmissions to humans5, any rabid mammal can cause an infection, including unvaccinated pets and wild animals. that’s why vaccinating both pets (even indoor) and wild animals are essential to rabies elimination. consistent with the planet Organisation for Animal Health (OIE), the vaccination of stray and owned dogs should be the primary priority. The organization further notes that wildlife vaccination has produced excellent leads to certain species and regions6. In countries that have successfully achieved herd immunity at a vaccination rate of a minimum of 70 percent of the whole dog population, human rabies cases should occur, if rarely. The Centers for Disease Control and Prevention (CDC) for instance report one or two human deaths annually within the U.S. thanks to travel abroad or exposure to wildlife, with the foremost common source being bats7.
Contributing towards global rabies control
Nigel Swift, Global Head of Veterinary Public Health at Boehringer Ingelheim, relays: “At least 59,000 people die per annum thanks to rabies8, and 40 percent people bitten by an animal suspected of carrying rabies are children5. the planet Health Organization suspects that these dramatic numbers are a gross underestimation9. These facts underpin our One Health mission. At Boehringer Ingelheim’s Veterinary Public clinic , we are proud to partner with health authorities, governments and NGOs in planning mass vaccination campaigns, also as providing affordable global access to our high-quality vaccines to support effective rabies control.”
Sophie Randoux, Global Head of Pet Vaccine Marketing, adds: “Boehringer Ingelheim supplies quite 100 million doses of rabies vaccines annually , a feat we are very pleased with . additionally to supplying governments and international organizations, we serve numerous private veterinary clinics in order that pet owners can protect their pets. Beyond vaccines, we supply clinics with a variety of educational materials to assist veterinarians inform the overall public and supply them with lifesaving knowledge. We are committed to continuing our joint efforts to stay people and animals safe from rabies.”
About World Rabies Day
World Rabies Day, persisted September 28 per annum , was initiated by GARC in 2007 to make a worldwide opportunity for people to unite in increasing awareness of rabies prevention. Since then, it’s grown year on year, with thousands of individuals organizing and participating in local, regional and national events, on or around September 28. Learn more at http://rabiesalliance.org/world-rabies-day
About the worldwide Alliance for Rabies Control
The Global Alliance for Rabies Control (GARC) is that the leading non-profit organization that aims to eliminate deaths from dog rabies by 2030. GARC works with governments, veterinary, public health and academic experts, and communities to facilitate about-face and build capacity to eliminate rabies in areas hardest hit by the disease. For more information about rabies and GARC’s work, visit https://rabiesalliance.org
Boehringer Ingelheim Animal Health
The lives of animals and humans are interconnected in deep and sophisticated ways. we all know that when animals are healthy, humans are healthier too. Across the world , our 9,700 employees are dedicated to delivering value through innovation, thus enhancing the well-being of both.
Boehringer Ingelheim
Boehringer Ingelheim is functioning on breakthrough therapies that improve the lives of humans and animals. As a number one research-driven biopharmaceutical company, the corporate creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve quite 130 markets within the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
Source link: https://www.boehringer-ingelheim.com/
